The endocannabinoid system, in the brain for example, has an effect on memory, control of movement, modulation of pain, development of nerve growth and plasticity, and the adaptability of the nervous system. It has an influence on sleep, appetite, anxiety and social behaviour to name but a few important functions. Outside the brain the endocannabinoid system is also widespread and has effects on the bladder, the bowels, the reproductive system, the heart, the hormonal and metabolic systems and has a role in the control of cancer. In other words, it is one of the most important bodily systems – yet one of the least understood.
We know that there are at least two cannabinoid receptors in the body, CB1 and CB2, but in the next few years we are certain that more receptors will be isolated. There are natural chemicals circulating in the body that attach to these receptors and it is through this chemical attachment that the endocannabinoid system performs its functions.
MD FRCP, HONORARY PROFESSOR OF NEUROLOGICAL REHABILITATION
We believe there are well over a hundred different cannabinoids in the plant, but, we only know a substantial amount about two (THC and CBD), a little about ten, and virtually nothing about the others. Thus, we have a long way to go to understand all the different properties and potential medical benefits of cannabinoids. THC is psychoactive and this gives individuals the cannabis “high”. CBD is not psychoactive and indeed, to an extent, counteracts the “high” of the THC. Thus, the balance between THC and CBD is one of the most crucial factors in understanding what effects will be seen in a particular cannabis variety.
Studies suggest that when legal cannabis is introduced into a population the number of opioid deaths reduces by at least 25%. Cannabis is now legal for medical purposes in 44 countries around the world and this number is increasing month by month. It is, in our view, the most exciting medical development of the early 21st century (source: The European Cannabis Report T M, Prohibition Partners)
CULTIVATE
The plants will be grown in a high security facility with climate controlled conditions. Cultivation to GAcP standards with EU GMP drying and processing.
EXTRACT
The extraction facility will be constructed alongside the cultivation within the same high security building. Extraction and Processing facility to EU GMP standards.
END PRODUCT
We intend to produce a cannabis based medicinal product (CBMP) suitable for specialist prescription to UK patients via our clinical and distribution partners.
